Example: Heart Attack

Clinical Trials on Malignant Carcinoid Syndrome

Total 64 results

NCT00092287

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Conditions: Malignant Carcinoid Syndrome
NCT01172717

Withdrawn

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Conditions: Carcinoid Syndrome
NCT02063659

Completed

Telotristat Etiprate for Carcinoid Syndrome Therapy

Conditions: Carcinoid Syndrome
NCT01430871

Completed

Effects of Serotonin Excess on Bone in Carcinoid Syndrome

Conditions: Carcinoid Syndrome
NCT01677910

Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Conditions: Carcinoid Syndrome
NCT01104415

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Conditions: Carcinoid Syndrome
NCT00884715

Terminated

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Conditions: Carcinoid Syndrome
NCT01018953

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Conditions: Carcinoid Syndrome
NCT00774930

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Conditions: Carcinoid Syndrome
NCT00853047

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Conditions: Carcinoid Syndrome
NCT02026063

Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Conditions: Carcinoid Syndrome
NCT01234168

Completed

A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea

Conditions: Neuroendocrine Tumors; Carcinoid Syndrome
NCT03223428

Recruiting

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

Conditions: Carcinoid Syndrome
NCT01932528

Completed

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

Conditions: Carcinoid Syndrome
NCT00412061

Completed

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Conditions: Carcinoid Tumor; Malignant Carcinoid Syndrome
NCT04713202

Not yet recruiting

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

Conditions: Neuroendocrine Tumors; Carcinoid Syndrome; Diarrhea
NCT00955604

Completed

Azilect + Antidepressant Chart Review

Conditions: Serotonin Syndrome
NCT04073017

Recruiting

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

Conditions: Neuroendocrine Tumor; Carcinoid Syndrome
NCT04140409

Terminated

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Conditions: Neuroendocrine Tumors; Carcinoid Syndrome
NCT03722511

Recruiting

Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

Conditions: Neuroendocrine Tumors; Carcinoid Tumor of GI System; Diarrhea; Carcinoid Syndrome
NCT01886287

Terminated

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Conditions: Neuroendocrine Carcinoma
NCT03220087

Completed

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain

Conditions: Neuroendocrine Tumors
NCT04065165

Withdrawn

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

Conditions: Small Intestinal NET; Carcinoid Heart Disease
NCT03453489

Unknown status

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm

Conditions: Carcinoid Syndrome; Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
NCT04039516

Not yet recruiting

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

Conditions: Carcinoid Heart Disease; Carcinoid Syndrome; Carcinoid Tumor